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Abstract
Taxane therapy remains the standard of care for triple-negative breast cancer. However, high 
frequencies of recurrence and progression in treated patients indicate that metastatic breast cancer 
cells can acquire resistance to this drug. The actin regulatory protein MENA, particularly its 
invasive isoform, MENAINV, are established drivers of metastasis. MENAINV expression is 
significantly correlated with metastasis and poor outcome in human breast cancer patients. We 
investigated whether MENA isoforms might play a role in driving resistance to chemotherapeutics. 
We find that both MENA and MENAINV confer resistance to the taxane paclitaxel, but not to the 
widely used DNA damaging agents doxorubicin or cisplatin. Furthermore, paclitaxel treatment 
does not attenuate growth of MENAINV-driven metastatic lesions. Mechanistically, MENA 
isoform expression alters the ratio of dynamic and stable microtubule populations in paclitaxel-
treated cells. MENA expression also increases MAPK signaling in response to paclitaxel 
treatment. Decreasing ERK phosphorylation by co-treatment with MEK inhibitor restored 
paclitaxel sensitivity by driving microtubule stabilization in MENA isoform-expressing cells. Our 
results reveal a novel mechanism of taxane resistance in highly metastatic breast cancer cells and 
identify a combination therapy to overcome such resistance.
*Corresponding author: Frank B. Gertler, Koch Institute for Integrative Cancer Research, MIT 76-361a, 77 Massachusetts Ave, 
Cambridge, MA 02139, 617-253-5511, fgertler@mit.edu. 
Disclosure of Potential Conflicts of Interest
F.B. Gertler has ownership interest (including patents) in MetaStat and is a consultant/advisory board member for the same. No 
potential conflicts of interest were disclosed by the other authors.
HHS Public Access
Author manuscript
Mol Cancer Ther. Author manuscript; available in PMC 2018 January 01.
Published in final edited form as:
Mol Cancer Ther. 2017 January ; 16(1): 143–155. doi:10.1158/1535-7163.MCT-16-0413.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Introduction
While the number of targeted agents in clinical trials for metastatic breast cancer continues 
to increase, chemotherapy remains the standard of care for this disease, particularly for 
triple-negative breast cancer (TNBC), one of the most aggressive breast cancer subtypes (1). 
TNBC, defined by a lack of expression of both estrogen and progesterone receptor as well as 
low levels of HER2, accounts for 15% of breast tumors. TNBC is associated with a poorer 
prognosis along with a greater risk of recurrence and metastasis (2,3). Platinum agents, 
taxanes and anthracyclines are used in mono- or poly-chemotherapy as front line treatment, 
especially in the context of metastatic disease (4). Anti-mitotic chemotherapy agents 
generally target proliferating cancer cells, with platinum agents such as Cisplatin and 
anthracyclines including Doxorubicin primarily functioning through direct interaction with 
DNA and subsequent interference with its replication. In contrast, taxanes such as paclitaxel 
lead to mitotic catastrophe by stabilizing microtubules (MTs) and inhibiting their 
disassembly during metaphase, thus leading to mitotic arrest and cell death (5)(6). The 
benefits of cytotoxic chemotherapy for TNBC are clear; nevertheless, response rates are low, 
and over 50% of TNBC patients become resistant to chemotherapy typically by 6–10 
months (7).
A number of cellular processes are known to drive chemo-resistance, which can arise from 
both cell intrinsic mechanisms as well as tumor microenvironment-driven external survival 
signals (8). First, changes in expression of the adenosine triphosphate-binding cassette 
(ABC) superfamily of transporters, in particular P-gp/MDR1, have been shown to be 
involved in paclitaxel resistance (9). While in vitro and pre-clinical studies showed increased 
cell death with dual chemotherapy and MDR1 inhibitor, the first and second generation of 
inhibitors both failed in clinical trials due to safety and efficacy issues (9). Second, 
mutations in a drug’s cellular targets, β-tubulin in the case of taxanes, can drive cell intrinsic 
resistance by impairing paclitaxel binding, increasing MT dynamics, and blocking taxane-
induced G2/M arrest (10). Third, changes in expression or function of proteins of the 
apoptosis pathways, such as caspase-3 or Bcl-2, have also been implicated in taxane 
resistance (11,12). Chemotherapy-induced pro-apoptotic signals can be counteracted by 
constitutive activation of the pro-survival PI3K/Akt/mTOR or RAF/RAS/MEK MAPK 
signaling pathways (13). Paclitaxel treatment can induce MAPK activation to attenuate MT 
stabilization (10), and multiple studies have demonstrated that co-treatment with paclitaxel 
and a MEK inhibitor can increase cancer cell death (14). Much of our understanding of these 
and other mechanisms of taxane resistance is derived from studies focused on cell survival 
and proliferation. The question of how such mechanisms of resistance are associated with 
cell invasion and metastatic disease itself remains understudied.
One key driver of breast cancer metastasis is MENA (also known as ENAH or hMena), a 
member of the Ena/VASP family of actin elongation factors that is upregulated in various 
cancer types, including breast cancer (15). MENA deficiency in the PyMT mouse model of 
breast cancer slows tumor progression and decreases metastasis (16), and stable depletion of 
MENA in the human breast adenocarcinoma MDA-MB-231 cells significantly decreases 
metastatic burden from orthotopic xenograft tumors (17). In addition to a broadly expressed 
80kDa MENA isoform, multiple other MENA protein isoforms can arise in some cell types 
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from changes in the inclusion of 5 alternatively-spliced exons in the MENA mRNA (18–20). 
In human breast cancer patients and in mouse breast cancer models, changes in expression 
of two functionally distinct isoforms, MENA11a and MENAINV, are linked to metastatic 
tumor cell phenotypes and to patient outcomes. MENA11a expression is high in normal 
epithelial tissues and in epithelial-like cells in breast cancer cells in vitro and in vivo (19,21), 
but is low in invasive tumor cell subpopulations (22). Mena11a suppresses tumor cell 
migration and invasion and promotes cohesive tumor morphology (19,21,23). While 
expression levels of either MENA or MENA11a alone do not correlate breast cancer patient 
outcome (17,24), patients with high Menacalc, a measure of the total Mena levels minus 
MENA11a levels, have poor disease-specific survival (24,25).
In contrast to MENA11a, MENAINV expression is significantly higher in metastatic 
compared to non-metastatic human breast tumors, and high levels of MENAINV, but not 
MENA, are associated with increased metastasis and poor outcome in multiple human breast 
cancer cohorts (17). MENAINV is highly upregulated in invasive tumor cell subpopulations 
in vivo, but found only at trace levels in even highly aggressive breast cancer cell lines in 
culture (22,26). Expression of MENAINV in breast tumor cells renders them more sensitive 
to multiple pro-invasive growth factors (27,28) and increases their ability migrate towards 
higher concentration of fibronectin, which is especially abundant near blood vessels (17). As 
a consequence, cells expressing MENAINV are more invasive and are highly metastatic. 
MENAINV has been shown to drive resistance to targeted tyrosine kinase inhibitors in 
growth-factor elicited motility responses (28), however its role in regulating responses to 
chemotherapeutic drugs has never been studied. Chemotherapy regimens containing taxanes 
are the standard of care for patients with metastatic breast cancer(29). Given the fact that 
both MENAINV and MENA are expressed in metastatic breast tumors and drive pro-
metastatic phenotypes, we wondered whether expression of MENA and MENAINV affected 
tumor cell responses to chemotherapy, and how, in turn, standard of care cytotoxic therapy 
might influence MENA/MENAINV-driven metastasis. We show, using in vitro and in vivo 
models, that highly metastatic cells expressing MENA or MENAINV confer paclitaxel 
resistance, by preventing the MT stabilization via activation of the MAPK signaling cascade. 
Our findings reveal a novel mechanism by which highly metastatic breast cancer cells can 
become resistant to taxanes.
Materials and methods
Antibodies and drugs
Antibodies—The anti-MENA and anti-MENAINV antibodies were generated in the 
laboratory and previously described (30,26), anti-tubulin (Sigma, DM1A), anti-tubulin 
detyrosinated or Glu-Tubulin (Millipore, AB3201), anti-tubulin tyrosinated (Millipore, 
ABT171), anti-pERK Y204 (Santa Cruz, sc7383), anti-GAPDH (Sigma, G9545), anti-Ki67 
(BD Biosciences), cleaved Caspase-3 (BD Biosciences), anti-pAkt473 (CST).
Drugs—Doxorubicin, Cisplatin and paclitaxel (Sigma), Docetaxel. For in vitro experiment, 
drugs were diluted in cell culture media with 1% of DMSO. Vehicle control correspond to 
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cells treated with culture media with 1% of DMSO (no drug), PD0325901 MEK inhibitor 
(LC Labs), MDR1 inhibitor HM30181 (100nM) gift from the Weissleder Lab (MGH)(31).
Cell Culture
MDA-MB-231 cells were purchased directly from the ATCC in June 2012, where cell lines 
are authenticated by short tandem repeat profiling. These cells were not reauthenticated by 
our lab and were cultured in DMEM with 10% FBS (Hyclone). Cell line generation and 
FACS were performed as previously described (32). Cell lines show a 8- to 10-fold 
overexpression relative to endogenous MENA, and are labeled 231-Control, 231-MENA and 
231-MENAINV (17). SUM159 cells were obtained from Joan Brugge’s lab at Harvard 
Medical School (January 2011) and were not reauthenticated in our lab. SUM159 cells were 
cultured according to the ATCC protocols. T47D cells were purchased at ATCC, where cell 
lines are authenticated by short tandem repeat profiling. They were cultured according to the 
manufacturer’s protocol, and not reauthenticated in our lab. Stable Knockdown cell lines 
(T47D) were generated using using a retroviral vector to express a mir30-based shRNA 
sequence ‘CAGAAGACAATCGCCCTTTAA’ targeting a sequence shared amongst all 
known Mena mRNA isoforms. By western blot analysis detected using an anti-Mena 
monoclonal that recognizes an epitope shared in all known Mena protein isoforms (33) 
indicated that expression of all molecular species detected were significantly reduced in the 
T47D-ShMena cell line; expression analysis of specific MENA isoforms was not performed. 
MDA-MB 175IIV, MDA-MB 453, MDA-MB 436, BT-549, LM2 and BT-20 were gifted by 
Dr Michael Yaffe’s lab (Koch Institute, MIT) in April 2015, and cultured according 
manufacturer’s protocol, and not reauthenticated by our lab.
Cell viability assay
Cell viability assays were performed in a 96-well plate. 5,000 cells were plated per well and 
treated with drug 24h later. Cell viability was assayed 72 hours later using the PrestoBlue 
Cell Viability Reagent (Life Technologies), according to manufacturer’s protocol. 
Fluorescence was measured and normalized to cells exposed to vehicle. The activity area 
was calculated from dose–response plots using Matlab. All measurements were repeated in 
triplicate.
Xenograft tumor generation and in vivo chemotherapy treatment
All animal experiments were approved by the MIT Division of Comparative Medicine. 2 
million MDA-MB-231 cells expressing different MENA isoforms (in PBS and 20% collagen 
I) were injected into the 4th right mammary fat pad of six week-old female NOD-SCID mice 
(Taconic). When the tumors reached 1 cm in diameter, mice were treated every five days 
with either three doses of paclitaxel at 10mg/kg in 1% DMSO, 3% PEG (MW 400), 1% 
Tween 80 in PBS by intra-peritoneal injection. In parallel, mice were treated with only in 
1% DMSO, 3% PEG (MW 400), 1% Tween 80 in PBS as a vehicle control. One day after 
the last injection, tumors were measured and mice were use for intravital imaging and then 
sacrificed. Their tumors and lungs were fixed in 10% formalin overnight, their bone marrow 
were collected using PBS and cultured in DMEM with 10% fetal bovine serum. The number 
of tumor cell colonies in cultured bone morrow was counted 1 month after collection. The 
number of metastasis in each lobe of the lung were counted from lung H&E stained sections 
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visualized by light microscopy and counted by two blinded individuals. Each tumor group 
contained 3–5 mice.
Intravital imaging
Intravital multiphoton imaging was performed as described previously (17) using a 25x 1.05 
NA water immersion objective with correction lens. After exposing the tumor with a skin 
flap surgery, 30 min movies were captured. The number of motile cells in each field of view 
were count in ten 30 min time-lapse movies using ImageJ. Motile cells were cells who show 
any displacement of the nucleus and cell protrusion activity. Data were pooled from 2–4 
mice per tumor group, with 4–10 fields imaged per mouse.
Western blot
Cells were lysed in 25mM Tris, 150mM NaCl, 10% glycerol, 1% NP 40 and 0.5M EDTA 
with a protease Mini-complete protease inhibitors (Roche) and a phosphatase inhibitor 
cocktail (PhosSTOP, Roche) at 4°C for 20 min. Protein lysates were separated by SDS-
PAGE, transferred to a nitrocellulose membrane and blocked with Odyssey Blocking Buffer 
(LiCor). Membranes were incubated with primary antibody overnight at 4°C and Licor 
secondary antibodies at room temperature for 1 hour. Protein level intensity was measured 
with Image J.
Immunohistochemistry
Tumors dissected from NOD/SCID mice were fixed in 10% buffered formalin and 
embedded in paraffin. Tissue sections (5μm thick) were deparaffinized followed by antigen 
retrieval using Citra Plus solution (Biogenex). After treatment with 3% H2O2, sections were 
blocked with serum, incubated with primary antibodies overnight at 4°C and fluorescently 
labeled secondary antibodies at room temperature for 2 hrs. Sections were stained using 
anti-MENA (1:500), biotinylated anti-MENAINV (1:500), anti-CC3 (1:200), anti-Ki67 
(1:200) and DAPI. Fluorochromes on secondary antibodies included AlexaFluor 488, 594 or 
647 (Jackson Immunoresearch). Sections were mounted in Fluoromount mounting media 
and imaged at room temperature. Z series of images were taken on a DeltaVision 
microscope using Softworx acquisition, an Olympus 40x 1.3 NA plan apo objective and a 
Photometrics CoolSNAP HQ camera. At least 10 fields were captured for each tumor, with 
at least 3 tumors per tumor group.
Human breast cancer expression analysis
Data retrieval from TCGA(34) (Fig S1A,B) was explained in (17). The data for MENAINV 
protein levels as measure by immunohistochemistry are also in (17), from patient samples 
obtained from (35).
In vitro imaging
Glass bottom dishes were coated with Collagen at 0.1 mg/ml diluted in PBS for 1 hour at 
37°C. Cells expressing different MENA isoform were treated with paclitaxel at 1, 10 or 100 
nM or vehicle and immediately plated on the glass bottom dishes. 30 min later, cells were 
imaged overnight, with one image acquired every 10 min for 16 hours on a Nikon spinning 
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disk with a 20X objective and an Andor/NeoZyla camera. Individual cells were manually 
tracked using ImageJ and Manual Tracking plug-in. Data were analyzed using the 
chemotaxis tool developed by IBIDI. For analysis of time spent in cell division, we 
measured the time between when the mother cell first rounds up, to when both daughter cells 
have spread out on substrate. The percentage of successful cell divisions was quantified by 
counting the number of cell divisions that lead to two surviving daughter cells. Data are 
pooled from at least 50 cells tracked in three independent experiments.
Cell cycle analysis
231-Control, 231-MENA and 231-MENAINV cells were treated with paclitaxel at 10nM or 
100nM or vehicle. After 16h of treatment, cells were trypsinized, wash in cold PBS, 
centrifuged at 1000 rpm for 3 min, resuspended in 1ml of ice cold PBS, fixed by adding 4 ml 
of ethanol at −20°C, and incubated at 4°C for 1 hour. After fixation, cells were washed with 
ice-cold PBS and centrifuged at 22,000 rpm for 20 min. DNA was stained using Propidium 
iodine at 50μg/ml and RNase A at 1mg/ml for 30 min at 37°C. DNA content was measured 
on a FACSCalibur cytometer (Becton-Dickinson California). Data were analyzed using 
Modfit software (Verity Software House), with appropriate gating on the FL2-A and FL2-W 
channels to exclude cell aggregates. 25,000 events were analyzed per sample.
Immunofluorescence
Glass bottom dishes (Mattek) were coated with Collagen at 0.1 mg/ml diluted in PBS and 50 
μg/ml FN for 1 hour at 37°C. Cells were plated for 1hr, and then treated with paclitaxel 
alone or in combination with MEKi for 24h. Cells were fixed for 20 min in 4% 
paraformaldehyde in PHEM buffer with 0.1% Gluteraldehyde, and then quenched with 
sodium borohydrate for 5mins. Cells were blocked with 2% BSA in TBS-0.1%TritonX-100 
for 30 mins, and incubated with primary antibodies and then secondary antibodies for 1hr 
each, at room temperature. Z series of images were taken on an Applied Precision 
DeltaVision microscope using Softworx acquisition, an Olympus 60x 1.4 NA plan apo 
objective and a Photometrics CoolSNAP HQ camera. Images were deconvolved using 
Deltavision Softworx software and objective specific point spread function. Images were 
analyzed with ImageJ, where the whole cell intensity levels of Tyr- or Glu-MT was 
measured. Images are pooled from at least 3 independent experiments.
MT length image analysis
MT images were processed with 1) a filament reconstruction algorithm that selects bona fide 
filaments and 2) a post-analysis that quantifies the properties of the MT network 
organization. For the filament reconstruction, briefly, the MT images were first filtered by 
multiple-scale steerable filter to enhance the curvilinear features. From the filtered images, 
the centerlines of possible filament fragments were detected and separated into high and low 
confidence sets. Some of low confidence filament fragments were linked to high confident 
fragments using iterative graph matching. The output of the reconstruction is a network of 
filaments each presented by an ordered chain of pixels and the local filament orientation. 
The MT length was calculated as the number of pixels converted to microns, per each 
identified filament. Overall, at least 2000 MTs were analyzed per condition, from at least 
two experiments.
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Results
MENA and MENAINV are associated with increased survival during paclitaxel treatment in 
vitro
To investigate a potential role for MENA in resistance to chemotherapy in breast cancer, we 
first asked whether endogenous MENA and MENAINV expression levels were associated 
with paclitaxel resistance. MENA and MENAINV are widely expressed in all main breast 
cancer subtypes, as measured by mRNA from TCGA samples, as well as at the protein level 
by immunohistochemistry(17) (FigS1A–C), with slightly higher expression in patients with 
Her2+ breast cancer. We then measured paclitaxel efficacy and quantified levels of 
endogenous MENA protein expression across cell lines from several human breast cancer 
types, including: Luminal A (MDA-MB 175IIV and T47D), HER2 positive (MDA-MD 453) 
and TNBC (SUM 159, BT-20, MDA-MB 436, LM2, BT-549, MDA-MB 231) (Fig 1A,B, 
Fig S1D). In addition to the canonical 80kDa MENA isoform, some the cell lines used 
express other MENA isoforms endogenously, such as MENA11a, which is known to be 
expressed in epithelial-like cell lines including T47D cells and absent from mesenchymal-
like cell lines including BT-549 and MDA-MB-231 cells. Under the conditions we used, 
MENA11a co-migrates with the 80kDa MENA, thus the intensity of the measured the 
80kDa MENA, detected with an antibody known to recognize all MENA isoforms, 
represents the total amount of 80kDa MENA plus MENA11a in the cell lines that express 
both isoforms. There was a significant inverse correlation between paclitaxel efficacy, as 
measured by cell survival, and levels of endogenous MENA expression (Fig 1C). To confirm 
that endogenously-expressed MENA promotes Paclitaxel resistance, we knocked down 
MENA in T47D cells, which normally express MENA and MENA11a (Fig S1E)(19,21). It 
is important to note that the shRNA used for these experiments targets a sequence common 
to all known MENA isoforms, thereby depleting MENA11a as well as MENA. Reducing all 
MENA isoform levels (> 75%) in T47D cells renders them more sensitive to Paclitaxel (Fig 
1D).
To study the role of MENA and MENAINV independently, we used a triple-negative breast 
adenocarcinoma cell line (MDA-MB-231), which endogenously expresses low levels of 
MENA and, like other cultured breast cancer cell lines only trace levels of MENAINV in 
vitro. As endogenous MenaINV expression is highly upregulated by aggressive tumor cells 
within the in vivo tumor microenvironment (17,22,26), we stably over-expressed GFP (231-
Control), GFP-tagged MENA (231-MENA) or MENAINV (231-MENAINV) at equivalent 
levels in this cell line to match the robust expression observed in vivo. We observed that the 
fraction of viable 231-MENA or 231-MENAINV cells was at least 65% higher than the 
fraction of viable 231-Control cells, after 72h of treatment with varying doses paclitaxel 
(Fig1E). To investigate the specificity of the response, we also tested two other commonly 
used chemotherapeutics, doxorubicin and cisplatin, and found that neither MENA nor 
MENAINV expression affected the response to the different concentrations of either drug 
(Fig S1F,G). These experiments revealed that cell viability in the presence of high paclitaxel 
concentrations is decreased with low MENA expression and increased by ectopic expression 
of MENA or MENAINV. These data suggest that the increased levels of MENA isoforms 
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observed in tumor cells during metastatic progression may contribute to paclitaxel 
resistance.
MENA isoform expression is associated with increased tumor growth in vivo during 
paclitaxel treatment
We then investigated whether MENA-associated paclitaxel resistance could also be observed 
in vivo. Xenograft tumors were generated by injecting MDA-MB-231 cells expressing 
MENA isoforms into the mammary fat pads of NOD-SCID mice. Mice were treated with 
paclitaxel once tumors reached 1cm in diameter (Fig 2A). Treatment with paclitaxel 
significantly decreased the growth of 231-Control tumors compared to mice treated with 
vehicle (Fig 2B). However, the growth of 231-MENA or 231-MENAINV tumors was 
unaffected by paclitaxel treatment (Fig 2B), thereby suggesting MENA and MENAINV 
promote drug resistance in vivo.
The increased size of paclitaxel-treated 231-MENA and 231-MENAINV tumors could arise 
from elevated levels of proliferation, decreased levels of cell death, or both. We evaluated 
proliferation and apoptosis by quantifying the intensity of cells positive for Ki67 and CC3, 
respectively by immunostaining. Although paclitaxel treatment decreased the amount of 
Ki67 staining in 231-Control tumors, it failed to decrease the numbers of Ki67-positive cells 
in 231-MENA and 231-MENAINV tumors (Fig 2C,D). In contrast, treatment did lead to an 
increase in cell death as marked by CC3 positive cells in all tumors (Fig 2E,F). These data 
indicate that during paclitaxel treatment of tumor bearing animals, MENA or MENAINV 
expressing tumor cells continue to proliferate, but exhibit similar rates of apoptosis to 
control tumors.
Paclitaxel treatment decreases cell velocity in vitro, but does not affect MENAINV-driven 
tumor cell motility and dissemination in mice
MENA and MENAINV drive increased cell motility and metastasis during tumor progression 
(17,27). Therefore, we examined whether MENA isoform expression impacts cell migration 
and dissemination after paclitaxel treatment. In vitro, paclitaxel treatment decreased velocity 
of the three MENA isoform expressing cell lines (Fig S2). However, at every concentration 
of the drug used, 231-MENAINV maintained higher velocity than cells expressing MENA or 
control cells. Using multiphoton intravital imaging we found that, in vivo, paclitaxel 
treatment significantly reduced the number of cells moving within 231-Control tumors. On 
the contrary, motility of 231-MENA and of 231-MENAINV tumor cells was not affected by 
the treatment (Fig 3A). To investigate the effect of paclitaxel treatment on metastatic burden, 
we counted the number of colonies in cultured bone morrow and the number of metastases 
in the lung from mice bearing 231-Control, 231-MENA or 231-MENAINV tumors for 12 
weeks. Neither the number of bone marrow colonies (Fig 3B), nor the number of lung 
metastases (Fig 3C,D) from 231-MENA or 231-MENAINV tumors were affected by 
treatment with paclitaxel. These data suggest that highly metastatic cells, such as those 
expressing MENA isoforms, are not affected by paclitaxel treatment in the context of 
metastatic disease.
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Paclitaxel treatment selects for high MENA expression in vitro and in vivo
Our results so far indicated that increased MENA or MENAINV expression levels are 
associated with reduced responses to paclitaxel. We next investigated the effect of paclitaxel 
treatment on levels of MENA expression in cell populations in vitro and in vivo. First, we 
analyzed endogenous MENA expression by Western Blot in 5 breast cancer cell lines that 
were exposed to 100nM of paclitaxel or a vehicle control (Fig 4A). We found that 72h after 
paclitaxel treatment, some cell lines (MDA-MB-231 and MDA-MB-175VII) showed 
increased MENA expression (Fig 4B). We performed a similar analysis using MDA-
MB-231 cell populations expressing heterogenous levels of either GFP, GFP-MENA or 
GFP-MENAINV. FACS analysis revealed that treatment with Docetaxel (a taxane closely 
related to paclitaxel) selected for cells expressing higher levels of GFP-MENA or GFP-
MENAINV, but not of GFP (Fig 4C). Finally, quantitative immunofluorescence analysis of 
tissue sections from 231-Control tumors taken from animals that were treated with either 
paclitaxel or a vehicle control revealed significant increases in total MENA levels, detected 
by a pan-MENA antibody, and in MENAINV levels, detected by an anti-MENAINV isoform 
specific antibody, in tumors from the paclitaxel-treated mice compared to vehicle (Fig 4D–
F). Together, these data indicate that, both in vitro and in vivo, paclitaxel treatment selects 
for tumor cells cells expressing a higher level of MENA and MENAINV.
MENA isoform-driven resistance does not involve drug efflux or focal adhesion signaling, 
but does affect cell division
We next investigated the mechanism by which MENA and MENAINV increase resistance to 
paclitaxel. Paclitaxel efflux through the MDR1 pump is one of the most frequent and best 
described mechanisms of paclitaxel resistance (9). Co-treatment with HM30181, a 3rd 
generation MDR1 inhibitor (31), and 100nM of paclitaxel negligibly affected the fraction of 
viable 231-Control cells and did not increase paclitaxel efficacy in 231-MENAINV cells (Fig 
S3A). Focal adhesion signaling has been reported to promote resistance to paclitaxel (36), 
and we previously reported that MENA regulates focal adhesion signaling via a direct 
between an LERER-repeat domain in MENA and the cytoplasmic tail of α5 integrin (32). 
To determine whether the interaction between MENA and α5 is required for increased 
resistance to paclitaxel, we assayed cells expressing α5-binding deficient versions of MENA 
or MENAINV (lacking the LERER-repeat domain) and found that these mutants versions 
were equally effective to the wild type versions in increasing resistance to paclitaxel (Fig 
S3B). These data indicate that neither drug efflux, nor the MENA-α5 interaction mediate 
MENA isoform-driven resistance to paclitaxel.
One of the key steps in paclitaxel-induced cell death is cell arrest in the G2/M phases of the 
cell cycle. We performed cell cycle analysis on 231-Control, 231-MENA and 231-
MENAINV cells treated with 10nM or 100nM of paclitaxel for 16h (Fig S4A–C), and found 
a similar dose-dependent increase of cells in the G2/M phase across all three cell lines. 
Therefore, MENA or MENAINV expression does not impair paclitaxel-induced arrest in 
G2/M, as measured in cells in suspension by flow cytometry. We next performed time-lapse 
microscopy to study the cell division phenotypes in more detail, and imaged cells expressing 
MENA isoforms while adherent on collagen (Fig S4D–F). Treatment with paclitaxel 
increased the time 231-Control cells spent rounded in cell division by four-fold, however, 
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231-MENA and 231-MENAINV showed only a two-fold increase in the time spent in cell 
division (Fig S4G). Furthermore, paclitaxel treatment led to a 40% decrease in the number 
of successful divisions in 231-Control cells, in which one cell divides into two surviving 
daughter cells (Fig S4H). In contrast, over 90% of cells divisions in paclitaxel treated 231-
MENA and 231-MENAINV cells were successful (Fig S4H). Together, these data suggest 
that MENA isoform expression confers the ability to progress through cell division more 
effectively and successfully during treatment with paclitaxel.
Expression of MENA is associated with increased ratio of dynamic to stable MTs during 
paclitaxel treatment
Paclitaxel promotes cell death by increasing the stability of MTs, and pathways driving 
increased MT dynamics are known to promote resistance to taxanes (10). Therefore, we 
examined MT structure and dynamics in MENA isoform expressing cells during paclitaxel 
treatment. We found that at baseline, 231-MENA and 231-MENAINV cells contained longer 
MTs (Fig S5A–C). Paclitaxel treatment had no effect on MT length in either 231-Control or 
231-MENA cells, but did elicit a small but significant increase in 231-MENAINV cells (Fig 
S5C). Post-translational modification of MTs can regulate their dynamics, and antibodies 
that detect such modifications can be used to infer the relative dynamics of MT populations; 
in particular, MT tyrosination indicates a dynamic MT state, while de-tyrosination of MTs is 
associated with increased stability (37). We measured the relative abundance of stable (Glu-
MT) vs. dynamic (Tyr-MT) MTs in individual cells by immunofluorescence with anti-Glu-
MT and anti-Tyr-MT antibodies (Fig 5A,B). In 231-Control cells, treatment with paclitaxel 
led to a significant increase in the relative ratio of stable to dynamic MTs. However, in both 
231-MENA and 231-MENAINV cells, there was no change in the relative levels of stable to 
dynamic MTs (Fig 5C). Together, these data demonstrate that MENA isoforms can affect 
MT length, and that MENA isoform expression maintains dynamic MTs during paclitaxel 
treatment.
MENA drives resistance to paclitaxel by increasing MAPK signaling
The MAPK signaling cascade is among the key pathways known to interact with MTs. Both 
ERK1/2 interact with MTs; MT stabilization by paclitaxel increases ERK phosphorylation 
and, in turn, ERK pathway activation increases MT dynamics (10). We measured levels of 
ERK phosphorylation in 231-Control, 231-MENA and 231-MENAINV cell lines after 72h of 
paclitaxel treatment. We found that 231-MENA and 231-MENAINV cells had higher levels 
of pERK Y204 relative to 231-Control cells, after paclitaxel treatment, while total ERK 
levels were unchanged in the same conditions (Fig 6A,B, Fig S6A,B). In contrast, treatment 
with paclitaxel decreased pAkt473 levels equally in all three cell lines, without significantly 
changing total Akt levels (Fig S6 C–F). We therefore asked whether MEK inhibition (MEKi) 
could make MENA isoform expressing cells more sensitive to paclitaxel. In all cell lines, we 
found significant additive effects between paclitaxel and MEKi PD0325901 in a 
proliferation assay (Fig 6C–E), where treatment with both drugs simultaneously led to a 
greater increase in cell death than with each drug alone. However, higher concentrations of 
each drug were needed in 231-MENA and 231-MENAINV cells to obtain high levels of cell 
death, relative to 231-Control cells. MEKi treatment blocked paclitaxel-induced ERK 
phosphorylation in 231-MENAINV cells (Fig 6F). Finally, we investigated the effect of 
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paclitaxel and MEKi treatment on MT dynamics in 231-MENAINV cells and found that 
treatment with both drugs simultaneously induced increases in stable MTs relative to 
dynamic MTs, while treatment with either drug alone had no effect (Fig 6G,H). Together, 
these data suggest that MENA isoforms drive resistance to paclitaxel via sustained MT 
dynamics and increased ERK signaling.
Discussion
Previous work has identified several MENA isoforms, in particular MENAINV, as key 
drivers of metastatic breast cancer, with high MENAINV levels being associated with 
increased recurrence and poor outcome in breast cancer patients (17). Our data highlight an 
additional, unexpected role for MENA and MENAINV in driving resistance to paclitaxel by 
maintaining dynamic MTs during paclitaxel treatment. We found that MENA and MENAINV 
expression maintains MT dynamics during paclitaxel treatment, leading to increased MAPK 
signaling. While taxanes remain the standard of care for metastatic breast cancer, our data 
suggest this class of drugs may not be as effective in targeting certain highly invasive, 
metastatic cells.
We observed an inverse correlation between the levels of endogenous MENA expression in 
cultured breast cancer cell lines and sensitivity to paclitaxel. Ectopic expression of MENA or 
MENAINV in cultured MDA-MB-231 cells, which have low levels of endogenous MENA, 
decreased sensitivity to paclitaxel. Conversely, in T47D cells, which endogenously express 
high levels of MENA and MENA11a, depletion of all MENA isoforms increased sensitivity 
to paclitaxel. Together these data indicate that MENA expression promotes resistance to 
paclitaxel. Since MENA11a as well as MENA is expressed T47D and some of the other cell 
lines in our analysis, it is possible that MENA11a can contribute to paclitaxel resistance, 
though we did not perform any experiments to address whether or not MENA11a plays a 
functional role in resistance to paclitaxel. In this context, however, it is of interest to note 
that, while a role for MENA11a in resistance to chemotherapy remains unknown, MENA11a 
expression contributes to resistance to PI3K inhibitors in HER-2 overexpressing breast 
cancer cells (38). While beyond the scope of this study, it will be interesting to determine the 
extent to which other MENA11a and other MENA isoforms may contribute to paclitaxel 
resistance, and how taxane therapy may affect expression of all MENA isoforms in patients.
Superficially, it may seem paradoxical that aggressive breast cancer cell lines such as MDA-
MB-231 and BT549, which express low levels of endogenous MENA and only trace levels 
of MENAINV when cultured in vitro. Our previous results indicate that MENA and 
MENAINV expression is upregulated significantly in aggressive tumor cell subpopulations 
when cultured breast cancer cells are implanted to make orthotopic tumors in 
immunocomprised mice (22). Therefore, it is likely that growth in the tumor 
microenvironment triggers changes in gene expression and alternative splicing in 
xenografted cells that increase the abundance of MENA and MENAINV during tumor 
progression, similar to the what is observed in autochtonous mouse mammary carcinomas 
and human breast tumors(26). As our goal in this study was to determine investigate how 
MENA isoform expression might affect breast cancer patients with aggressive, potentially 
metastatic disease, we designed our experiments based on knowledge derived from studies 
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of MENA isoform expression in tumor cells in vivo. To mimic the effect of the tumor 
microenvironment on MENA isoform expression for analyses in vitro, we engineered MDA-
MB-231 cells to express MENA or MENAINV, the two isoforms expressed in patients with 
aggressive, metastatic breast cancer. Our experiments demonstrated that MENA isoforms 
expressed in metastastic tumors confer resistance to paclitaxel, and, conversely, that 
paclitaxel treatment results in increased expression of MENA and MENAINV in tumors. 
Since we found that paclitaxel treatment was less effective in reducing metastatic burden in 
tumors with elevated MENAINV, it is possible that taxane-based therapy may, in some cases, 
trigger elevated expression MENAINV expression that, in turn, both promotes metastasis and 
decreases the efficacy of the treatment. Studies to invesitigate this possibility are underway.
How might MENA/MENAINV promote resistance to taxanes? We initially hypothesized that 
MENA’s role in regulating focal adhesion (FA) signaling may be important in this context, 
given the established links between FAs and MTs (39), as well as the known abundance of 
MENA at FA sites and its direct interaction with the α5 integrin subunit (17,32). We found, 
however, that interaction with α5 was not required MENA-dependent increases in taxane 
resistance (Fig S2). After paclitaxel treatment, MENA-expressing cells showed an increase 
in the abundance of dynamic MT populations, in paclitaxel-treated cells (Fig 5). Therefore, 
it will be interesting to understand whether MENA influences MTs via association with MT-
binding proteins, through an effect on signaling pathways that regulate MT dynamics, or 
both.
Interestingly, under control conditions, our data show that MENA or MENAINV expression 
increased MT length, support a role for MENA in regulation of MT behavior (Fig S4). 
Consistent with these findings, siRNA depletion of Enabled (Ena), the sole Drosophila 
MENA ortholog (18) in Drosophila S2 cells induced significant changes in MT dynamics, 
suggesting a potentially evolutionarily conserved role for MENA in regulating MT 
dynamics. However, under control conditions, we did not detect any changes in tyrosination 
at the whole cell level, which may be due to the fact that whole cell immunofluorescence is 
not sensitive enough to detect subtle differences (Fig 5). It is clear, however, that some actin 
regulatory proteins can regulate MT dynamics. For example, formins, actin nucleating and 
elongation factors, can also act as positive regulators of MT organization and stability (40). 
For example, complexes containing the activated forms of the formins mDia1 and INF2 
along with the scaffolding, and MT-binding protein IQGAP1 can increase MT stabilization 
via direct interaction with MTs (41), and MT regulators can also influence formin-dependent 
actin dynamics (42). Interestingly, a genetic screen in Drosophila identified Ena as a dosage-
sensitive modifier of phenotypes associated with ectopic expression of the MT +TIP 
tracking protein CLASP (43). Therefore, future work focused on the interplay between the 
actin-based cell motility machinery and MT regulation using fluorescent reporters for MT 
tip proteins coupled to live imaging may yield additional insight into the acquisition of 
taxane resistance by metastatic cancer cells.
Paclitaxel resistance driven by MENA isoforms leads to sustained MT dynamics that, in 
turn, lead to increased ERK signaling, at least in vitro (Fig 6). Disruption of MT dynamics 
can lead to ERK phosphorylation, and MAPK activation can inhibit MT stabilization 
(14,44,45). Therefore, a feedback mechanism may act to balance MAPK pathway activity 
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with MT dyanmics. Our data indicating that combined treatment with paclitaxel and MEKi, 
but not with either drug individually, leads to increased MT stability in MENAINV cells, 
raises the possibility that MENAINV alters the balance between MAPK singaling and MT 
dynamics (Fig 6). In a breast cancer cohort, MENA expression, as assessed by IHC, 
correlated with pERK and pAkt staining, with a higher number of pERK and pAkt positivity 
in MENA-positive tumors, irrespective of Her-2 status (46). Depletion of all MENA 
isoforms in the MCF7 Her2-overpressing line decreased ERK signaling, and inhibited EGF/
NRG1 mediated effects on cell proliferation (46). These data are consistent with a potential 
role for MENA in regulating ERK signaling. Alternatively, activation of bypass signaling 
pathways such as the Akt pathway, occurs downstream of integrins in response to paclitaxel 
treatment, even in the absence of differences in G2/M arrest (47). Interestingly, there were 
no MENA-isoform induced differences in the levels of Akt phosphorylation (Fig S6), which 
were significantly decreased in all three cell lines, during paclitaxel treatment. This finding 
is also consistent with our in vivo data showing that during paclitaxel treatment, MENA 
isoform expression selectively increases proliferation, which is relatively more senstive to 
MAPK signaling, but not apoptosis, which is relatively more sensitive to Akt signaling. 
Finally, our data suggest that combined treatment with a taxane with a MEKi could bypass 
MENA-isoform driven resistance (Fig 6). Several groups have previously shown that 
treatment with a MEKi can enhance paclitaxel-driven cell death in vitro and in vivo (48–50). 
Multiple clinical trials are currently underway in advanced solid tumors, such as melanoma 
and non-small cell lung cancer, testing combinations of taxanes and the MEK inhibitor 
Trametinib (51).
Our data reveal an interesting relationship between the response of highly metastatic cells to 
taxanes, as well as the effect of taxanes on highly metastatic cell populations in tumors, that 
could have important clinical implications. First, following paclitaxel treatment, MENA and 
MENAINV protein expression was higher in both in vitro and in xenograft tumors, 
suggesting that residual surviving cells have undergone a selection for increased MENA and 
MENAINV levels (Fig 4). Second, we found that MENAINV-driven tumor cell motility and 
metastasis is not affected by paclitaxel treatment (Fig 3). Paclitaxel is widely used as 
adjuvant therapy to prevent breast tumor relapse and metastasis (52). Our data suggest that 
paclitaxel may be less effective in treating patients that have primary tumors expressing high 
levels of MENAINV. While here we focused on triple-negative breast cancer, reduction in 
MENA levels in ER+ breast cancer cells also altered sensitivity to Paclitaxel (Fig 1), raising 
the possibility that this mechanism may be important in other subtypes. Currently, there are 
no biomarkers that predict response to taxanes in patients (53). MENA isoforms are being 
developed as biomarkers in breast cancer to predict metastatic potential and to guide patient 
treatment (54). We also recently developed a MENAINV isoform specific antibody and used 
it to demonstrate that metastatic tumors express higher MENAINV than non-metatastic 
primary tumors, and that high MENAINV protein levels were significantly associated with 
poor outcome and recurrence in a breast cancer patient cohort (17,26). While further work is 
needed to establish a clear link between MENAINV expression and resistance to paclitaxel in 
patients, it will be interesting to study how paclitaxel increases MENAINV expression and 
whether this may contribute to a more aggressive phenotype in post-treatment residual tumor 
cell populations.
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Figure 1. Expression of MENA isoforms is associated with paclitaxel resistance
(A) Representative western blot of lysate prepared from the panel of breast cancer cell lines 
MDA-MB 175IIV and T47D (Luminal A, square), MDA-MB 453 (HER2+, triangle), MDA-
MB 436, BT-549, LM2, SUM159, MDA-MB 231 and BT-20 (TNBC, circle), probed with 
anti-MENA and anti-Tubulin antibodies (n=3). MENA expression level was assessed by 
measuring intensity of 80kDa band. (B) Cell viability at 72h was assessed for the same cell 
lines as in A, showing mean dose response across n=3. (C) Linear correlation between 
MENA protein expression (A) and paclitaxel efficacy, here defined as the inverse of the area 
under the dose response in B (n=3). (D) Cell viability in T47D cells expressing ShCtrl or 
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ShMENA after 72h of treatment with paclitaxel, determined using Prestoblue assay. (E) Cell 
viability was assessed in 231-Control, 231-MENA or 231-MENAINV cells after 72h of 
treatment with paclitaxel, determined using Prestoblue assay. The cell viability is expressed 
as a fraction relative to untreated cells. Data presented as mean± SEM for three independent 
experiments, each performed in duplicate. Statistics determined by unpaired t-test with 
Welch’s correction, where *** p<0.001, ** p<0.01, * p<0.05.
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Figure 2. MENA or MENAINV expression weakened paclitaxel effect on tumor growth in vivo
(A) Tumors were generated by injection of 231-Control, 231-MENA or 231-MENAINV cells 
in the mammary fat pad of NOD SCID mice. When tumors reached 1cm in diameter, mice 
were treated with paclitaxel every 5 days, 3 doses at 10mg/kg IP. Tumor volume was 
measured before and after treatment. (B) Relative change in tumor volume after treatment 
with paclitaxel of tumors expressing the different GFP-tagged MENA isoforms. Data 
presented as mean± SEM for at least 9 mice in each group. Statistics determined by unpaired 
t-test, where *** p<0.001, ** p<0.01, * p<0.05. (C) Representative images tumor sections 
from 231-Control, MENA and MENAINV, treated with vehicle or paclitaxel, and stained for 
the proliferation marker Ki67 (green). Scale bar is 100μm. (D) Quantification of the Ki67 
staining intensity in 231-Control, MENA and MENAINV tumors, with and without paclitaxel 
treatment. (E) Representative images tumor sections from 231-Control, MENA and 
MENAINV, treated with vehicle or paclitaxel, and stained for the apoptosis marker Cleaved-
Caspase 3 (CC3) (green). Scale bar is 100μm. (F) Quantification of the CC3 staining 
intensity in 231-Control, MENA and MENAINV tumors, with and without paclitaxel 
Oudin et al. Page 20
Mol Cancer Ther. Author manuscript; available in PMC 2018 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
treatment. Data presented as mean± SEM for at 3 mice in each group, with at least 5 fields 
of view per tumor. Statistics determined by unpaired t-test, where *** p<0.001, ** p<0.01, * 
p<0.05.
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Figure 3. Paclitaxel treatment does not affect MENAINV-driven tumor cell motility and 
dissemination in mice
(A) Quantification of motile cells by multiphoton intravital imaging in tumors expressing 
MENA, MENAINV or Control. Tumors grown in mice treated with paclitaxel or vehicle. 
Data presented as mean± SEM, pooled from at least 3 mice per condition, with at least 2 
fields of view per mouse. (B) Number of disseminated tumor cells corresponding to the 
number of colonies in cultured bone marrow collected from mice bearing 231-Control, 231-
MENA or 231-MENAINV tumors, 12 weeks after injection. (C) Representative images of 
H&E stained lungs from mice bearing Control, 231-MENA or 231-MENAINV tumors, 
treated with vehicle or paclitaxel. Scale bar is 100μm. (D) Number of metastases in lung of 
mice bearing Control, 231-MENA or 231-MENAINV tumors 12 weeks after injection. Data 
presented as mean± SEM for at least 3 mice per group. Statistics determined by unpaired t-
test, where *** p<0.001, ** p<0.01, * p<0.05.
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Figure 4. Paclitaxel treatment selects for high MENA expression in vitro and in vivo
(A) Representative western blot of whole cell lysates prepared from multiple breast cancer 
cell lines treated with 100nM paclitaxel or DMSO as vehicle for 72 hours and probed with 
anti-MENA and anti-GAPDH antibodies. Images are not all from the same blots. (B) 
Quantification of endogenous MENA levels after 100nM paclitaxel relative to DMSO-
treated. Data presented as mean± SEM for three independent experiments. (C) FACS 
analysis of GFP expression levels of 231-Control, 231-MENA and 231-MENAINV cells 
treated with Docetaxol for 72hrs. The number shows the fold change in GFP signal relative 
to 231-Control cells. (D) Representative images of FFPE section from 231-Control tumor 
grown in mice treated with paclitaxel or with vehicle and stained for MENA (green), 
MENAINV (red) and DAPI (blue). Scale bar = 200μm. Mean of MENA (E) and MENAINV 
(F) fluorescence signal intensity. Data presented as mean± SEM for 10 fields of view per 
tumor, from 3 different mice. Statistics determined by unpaired t-test, where * p<0.05.
Oudin et al. Page 23
Mol Cancer Ther. Author manuscript; available in PMC 2018 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 5. MENA expression alters MT dynamics during paclitaxel treatment
Representative images of 231-Control (A) and 231-MENAINV (B) cells treated with 
paclitaxel (10nM) for 24h, and immunostained for detyrosinated or Glu-Tubulin (red) and 
tyrosinated or Tyr-Tubulin (green). Scale bar is 1 μm, and 0.25 μm in inset. (C) 
Quantification of the ratio of Glu-MT relative to Tyr-MT in 231-Control, MENA or 
MENAINV cells treated with vehicle (0.01% DMSO) or 10nM paclitaxel for 24h. Data 
presented as mean± SEM. Data pooled from 3 separate experiments, at least 8 cells analyzed 
per experiment. Statistics determined by one-way ANOVA, where *** p<0.001, ** p<0.01, 
* p<0.05.
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Fig 6. MENA isoforms confer resistance to paclitaxel by increasing MAPK signaling
(A) Representative Western Blot for pERK Y204 for in 231-Control, MENA or MENAINV 
cells treated with vehicle (0.01% DMSO), 10 or 100nM paclitaxel for 72h. Loading control 
is GAPDH. (B) Quantification of Western Blot shown in A, for pERK relative to GAPH. 
Data pooled from 4 experiments, two technical replicates per experiment. 231-Control (C), 
231-MENA (D) and 231-MENAINV (E) cells were treated with varying combinations of 
MEKi PD0329501 and paclitaxel for 72h, after which cell count was measured (shown as 
numbers and heatmap as a fraction of the max cell count for each plate). (F) Representative 
Western Blot for pERK Y204 for 231-MENAINV cells treated with vehicle (0.01% DMSO), 
10nM paclitaxel, 0.1 μM PD0329501 alone or in combination for 72h. Loading control is 
GAPDH. (G) Representative images 231-MENAINV cells with vehicle (0.01% DMSO), 
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10nM paclitaxel, 0.1 μM PD0329501 alone or in combination for 24h, and immunostained 
for detyrosinated or Glu-Tubulin (red) and tyrosinated or Tyr-Tubulin (green). Scale bar is 
1μm, 0.25 μm in inset. (H) Quantification of the ratio of Glu-MT relative to Tyr-MT in 231-
MENAINV cells treated with vehicle (0.01% DMSO) or 10nM paclitaxel for 24h. Data 
pooled from 3 separate experiments, at least 8 cells analyzed per experiment. Data presented 
as mean± SEM. Statistics determined by one-way ANOVA, where *** p<0.001, ** p<0.01, 
* p<0.05.
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